These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9071714)

  • 1. Danaparoid sodium lowers proteinuria in diabetic nephropathy.
    van der Pijl JW; van der Woude FJ; Geelhoed-Duijvestijn PH; Frölich M; van der Meer FJ; Lemkes HH; van Es LA
    J Am Soc Nephrol; 1997 Mar; 8(3):456-62. PubMed ID: 9071714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2.
    van der Pijl JW; Lemkes HH; Frölich M; van der Woude FJ; van der Meer FJ; Van Es LA
    J Am Soc Nephrol; 1999 Jun; 10(6):1331-6. PubMed ID: 10361873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of danaparoid sodium on hard exudates in diabetic retinopathy.
    van der Pijl JW; van der Woude FJ; Swart W; van Es LA; Lemkes HH
    Lancet; 1997 Dec; 350(9093):1743-5. PubMed ID: 9413466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 5. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
    JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danaparoid sodium in diabetic retinopathy.
    Gambaro G
    Lancet; 1998 Feb; 351(9103):674. PubMed ID: 9500356
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative review of the adverse effect profiles of heparins and heparinoids.
    Borris LC; Lassen MR
    Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparinoids Danaparoid and Sulodexide as clinically used drugs.
    Dou H; Song A; Jia S; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():55-74. PubMed ID: 31030761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Danaparoid for anticoagulation with Cell Saver 5. Answer to the letter of A. Lorentz].
    von Lüpke U
    Anaesthesist; 2001 Oct; 50(10):793. PubMed ID: 11702331
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.
    Minakata D; Fujiwara SI; Hayakawa J; Nakasone H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Ohmori T; Kanda Y
    Acta Haematol; 2020; 143(3):250-259. PubMed ID: 31461700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is it safe and cost effective... Danaparoid (Orgaran) as an anticoagulant for mechanical autotransfusion with Cell Saver 5 (Hemonetics),Anaesthesist (2001) 50:26-31].
    Lorentz A
    Anaesthesist; 2001 Oct; 50(10):792. PubMed ID: 11702330
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract]   [Full Text] [Related]  

  • 19. Delayed-type skin reaction to the heparin-alternative danaparoid.
    Szolar-Platzer C; Aberer W; Kränke B
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure.
    Westphal K; Martens S; Strouhal U; Matheis G; Lindhoff-Last E; Wimmer-Greinecker G; Lischke V
    Thorac Cardiovasc Surg; 1997 Dec; 45(6):318-20. PubMed ID: 9477469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.